Anti-tumor therapy with macroencapsulated endostatin producer cells

BMC Biotechnology

Volumn 10, Issue , 2010, Pages

  Rodrigues, Danielle B ^a   Chammas, Roger ^b   Malavasi, Natália V ^a   da Costa, Patrícia L N ^b   Chura Chambi, Rosa M ^a   Balduino, Keli N ^a   Morganti, Ligia ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANTI-TUMORS; ENDOSTATINS; GROWTH INHIBITION; IMMUNE REJECTION; IMMUNO-ISOLATION; IMMUNOSTAINING; MACRO-ENCAPSULATION; MELANOMA TUMORS; NEOVASCULARIZATION; POLYTETRAFLUOROETHYLENE MEMBRANES; POTENT INHIBITOR; THERAPEUTIC PROTEIN; THERAPEUTIC STRATEGY; TISSUE INTERFACE; TUMOR CELLS; TUMOR GROWTH; VASCULAR STRUCTURES;

BEARING PADS; BEARINGS (STRUCTURAL); CELL CULTURE; DERMATOLOGY; FIBROBLASTS; MAMMALS; ONCOLOGY; SYSTEMS ANALYSIS;

TUMORS;

ENDOSTATIN; POLITEF; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL ENCAPSULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EHRLICH ASCITES TUMOR; FIBROBLAST; IMMUNOHISTOCHEMISTRY; MACROENCAPSULATION; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; C3H MOUSE; C57BL MOUSE; CELL TRANSPLANTATION; EXPERIMENTAL MELANOMA; IMPLANT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SECRETION;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CELL TRANSPLANTATION; ENDOSTATINS; FIBROBLASTS; IMPLANTS, EXPERIMENTAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77950626286     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-10-19     Document Type: Article

References (26)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
2. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333(26):1757-1763. 10.1056/NEJM199512283332608, 7491141.
3. Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008, 13:6537-6553. 10.2741/3173, 18508679.
4. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285. 10.1016/S0092-8674(00)81848-6, 9008168.
5. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390(6658):404-407. 10.1038/37126, 9389480.
6. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001, 19(1):35-39. 10.1038/83481, 11135549.
7. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 2001, 61(18):6830-6837.
8. Zhang Y, Wang W, Xie Y, Yu W, Lv G, Guo X, Xiong Y, Ma X. Optimization of microencapsulated recombinant CHO cell growth, endostatin production, and stability of microcapsule in vivo. J Biomed Mater Res B Appl Biomater 2008, 84(1):79-88.
9. Zhang Y, Wang W, Zhou J, Yu W, Zhang X, Guo X, Ma X. Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO cells. Ann Biomed Eng 2007, 35(4):605-614. 10.1007/s10439-007-9255-4, 17277990.
10. Teng H, Zhang Y, Wang W, Ma X, Fei J. Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells. Acta Biochim Biophys Sin (Shanghai) 2007, 39(4):278-284. 10.1111/j.1745-7270.2007.00273.x, 17417683.
11. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 1995, 29(12):1517-1524. 10.1002/jbm.820291208, 8600142.
12. Brauker J, Martinson LA, Young SK, Johnson RC. Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation 1996, 61(12):1671-1677. 10.1097/00007890-199606270-00002, 8685942.
13. Michaels J, Dobryansky M, Galiano RD, Bhatt KA, Ashinoff R, Ceradini DJ, Gurtner GC. Topical vascular endothelial growth factor reverses delayed wound healing secondary to angiogenesis inhibitor administration. Wound Repair Regen 2005, 13(5):506-512. 10.1111/j.1067-1927.2005.00071.x, 16176459.
14. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, Timpl R, Werner S. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. Faseb J 2000, 14(15):2373-2376.
15. Malavasi NV, Rodrigues DB, Chammas R, Chura-Chambi RM, Barbuto JAM, Balduino K, Nonogaki S, Morganti L. Continuous and high level in vivo delivery of endostatin from recombinant cells encapsulated in TheraCyte immunoisolation devices. Cell Transplantation
16. Lage AP, Andrade SP. Assessment of angiogenesis and tumor growth in conscious mice by a fluorimetric method. Microvasc Res 2000, 59(2):278-285. 10.1006/mvre.1999.2217, 10684733.
17. Silva AE, Santos FGA, Cassali GD. Cell proliferation markers for evaluating the growth of solid and ascitic forms of Ehrlich tumor. Arq Bras Med Vet Zoo 2006, 58(4):658-661.
18. Silva AE, Serakides R, Ferreira E, Moraes JR, Ocarino Nde M, Cassali GD. Effect of hypothyroidism on the solid form of Ehrlich tumor in intact or castrated adult female mice. Arq Bras Endocrinol Metabol 2004, 48(6):867-874.
19. Coutinho EL, Andrade LN, Chammas R, Morganti L, Schor N, Bellini MH. Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma. Faseb J 2007, 21(12):3153-3161. 10.1096/fj.07-8412com, 17513560.
20. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997, 76(2):238-243. 2223937, 9231925.
21. Sweet IR, Yanay O, Waldron L, Gilbert M, Fuller JM, Tupling T, Lernmark A, Osborne WR. Treatment of diabetic rats with encapsulated islets. J Cell Mol Med 2008, 12(6B):2644-2650. 10.1111/j.1582-4934.2008.00322.x, 18373735.
22. Elliott RB, Escobar L, Calafiore R, Basta G, Garkavenko O, Vasconcellos A, Bambra C. Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant P 2005, 37(1):466-469.
23. Binette TM, Seeberger KL, Lyon JG, Rajotte RV, Korbutt GS. Porcine endogenous retroviral nucleic acid in peripheral tissues is associated with migration of porcine cells post islet transplant. Am J Transplant 2004, 4(7):1051-1060. 10.1111/j.1600-6143.2004.00460.x, 15196061.
24. Sorenby AK, Kumagai-Braesch M, Sharma A, Hultenby KR, Wernerson AM, Tibell AB. Preimplantation of an immunoprotective device can lower the curative dose of islets to that of free islet transplantation - Studies in a rodent model. Transplantation 2008, 86(2):364-366. 10.1097/TP.0b013e31817efc78, 18645504.
25. Garkavenko O, Emerich DF, Muzina M, Muzina Z, Vasconcellos A, Ferguson AB, Cooper IJ, Elliott RB. Xenotransplantation of neonatal porcine liver cells. Transplant P 2005, 37(1):477-480.
26. Yanay O, Barry SC, Flint LY, Brzezinski M, Barton RW, Osborne WR. Long-term erythropoietin gene expression from transduced cells in bioisolator devices. Hum Gene Ther 2003, 14(17):1587-1593. 10.1089/104303403322542239, 14633401.